Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.53 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.53 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.43 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | GABRA5 | P31644 | 1/20 | 0.43 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.43 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.43 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.43 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.43 |
| ▸ | AKR1B1 | P15121 | 2/20 | 0.42 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1951863 | 0.90 | GABRA1 (0.63) | GABRA1GABRB2POLBMEN1MAPT | |
| SCHEMBL774628 | 0.86 | GABRA1 (0.54) | GABRA1GABRB2POLBMEN1MAPT | |
| SCHEMBL5972997 | 0.84 | GABRA1 (0.53) | GABRA1GABRB2POLBMEN1MAPT | |
| SCHEMBL5208440 | 0.84 | GABRA1 (0.53) | GABRA1GABRB2POLBMEN1MAPT | |
| SCHEMBL8635378 | 0.82 | LTA4H (0.51) | GABRA1GABRB2POLBMEN1MAPT | |
| SCHEMBL2490536 | 0.81 | GABRA1 (0.66) | GABRA1GABRB2POLBMEN1MAPT | |
| SCHEMBL8633405 | 0.81 | GABRA1 (0.49) | GABRA1GABRB2POLBMEN1MAPT | |
| SCHEMBL11122677 | 0.80 | GABRA1 (0.47) | GABRA1GABRB2POLBMEN1MAPT | |
| SCHEMBL26982529 | 0.79 | GABRA1 (0.46) | GABRA1GABRB2POLBMEN1MAPT | |
| SCHEMBL5209444 | 0.79 | POLB (0.58) | GABRA1GABRB2POLBMEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-102584754-B | There is the fused aromatic compounds of anti-diabetic activity | SCHERING CORPORATION (US) | 2016-02-03 | — | — | CN | disclosed |
| EP-1861382-B1 | FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY | MERCK SHARP & DOHME (US) | 2012-10-10 | — | — | EP | disclosed |
| CN-102584754-A | Fused aromatic compounds having anti-diabetic activity | MERCK SHARP & DOHME | 2012-07-18 | — | — | CN | disclosed |
| US-7834036-B2 | Fused-aromatic compounds having anti-diabetic activity | MERCK SHARP & DOHME CORP (US) | 2010-11-16 | — | — | US | disclosed |
| US-7807692-B2 | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK SHARP & DOHME CORP. (US) | 2010-10-05 | — | — | US | disclosed |
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | MERCK SHARP & DOHME CORP. | 2010-07-01 | — | — | US | disclosed |
| EP-1907381-A4 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-20080194586-A1 | Fused-Aromatic Compounds Having Anti-Diabetic Activity | MERCK SHARP & DOHME LLC | 2008-08-14 | — | — | US | disclosed |
| EP-1907381-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | Merck & Co., Inc. (US) | 2008-04-09 | — | — | EP | disclosed |
| CN-101128441-A | Fused aromatic compounds having anti-diabetic activity | MERCK & CO INC (US) | 2008-02-20 | — | — | CN | disclosed |
| EP-1861382-A1 | FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY | Merck & Co., Inc. (US) | 2007-12-05 | — | — | EP | disclosed |
| US-20070173434-A1 | Antidiabetic oxazolidinediones and thiazolidinediones | MERCK SHARP & DOHME CORP. | 2007-07-26 | — | — | US | disclosed |
| EP-1709014-B1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO INC (US) | 2007-05-30 | — | — | EP | disclosed |
| WO-2007008501-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO., INC. (US) | 2007-01-18 | — | — | WO | disclosed |
| EP-1709014-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | Merck & Co., Inc. (US) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006096564-A1 | FUSED AROMATIC COMPOUNDS HAVING ANTI-DIABETIC ACTIVITY | MERCK & CO., INC. (US) | 2006-09-14 | — | — | WO | disclosed |
| WO-2005070905-A1 | ANTIDIABETIC OXAZOLIDINEDIONES AND THIAZOLIDINEDIONES | MERCK & CO., INC. (US) | 2005-08-04 | — | — | WO | disclosed |
| US-4391995-A | 4-Phenoxy-phenoxy-alkane-carboxylic acid derivatives and process for their manufacture | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-07-05 | — | — | US | disclosed |
| US-4301295-A | ANTILIPEMIC AND ANTICHOLESTEROL AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1981-11-17 | — | — | US | disclosed |
| US-4238626-A | ANTICHOLESTEROL AND ANTILIPEMIC AGENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1980-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194586-A1 | Fused-Aromatic Compounds Having Anti-Diabetic Activity | PPARG, PPARA, FABP4 | GABRA1 2030/4885GABRB2 1159/4885POLB 1732/4885 |
| US-20100168164-A1 | Antidiabetic Oxazolidinediones and Thiazolidinediones | PPARD, PPARA, PPARG | GABRA1 1549/4885GABRB2 480/4885POLB 2151/4885 |
| US-20070173434-A1 | Antidiabetic oxazolidinediones and thiazolidinediones | PPARD, PPARA, PPARG | GABRA1 1845/4885GABRB2 694/4885POLB 1824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.